Published in Blood on May 15, 1996
The ITP syndrome: pathogenic and clinical diversity. Blood (2009) 2.83
Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood (2010) 2.21
Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood (2012) 1.70
Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood (2008) 1.63
Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest (1998) 1.33
Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol (2012) 1.17
Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica (2009) 1.11
Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood (2011) 1.09
A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood (2005) 1.03
The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica (2011) 1.01
Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura. Blood Transfus (2011) 0.97
Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PLoS One (2011) 0.94
Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol (2009) 0.94
Immune dysregulation in immune thrombocytopenia. Semin Hematol (2013) 0.92
Platelets present antigen in the context of MHC class I. J Immunol (2012) 0.91
High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. Haematologica (2009) 0.90
Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia. Lab Invest (2014) 0.85
Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells. Stem Cells Dev (2011) 0.84
Piecing together the humoral and cellular mechanisms of immune thrombocytopenia. Semin Thromb Hemost (2011) 0.84
MicroRNA regulate immunological pathways in T-cells in immune thrombocytopenia (ITP). Blood (2013) 0.84
Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. Blood (2014) 0.82
DNA methyltransferase 3B gene promoter and interleukin-1 receptor antagonist polymorphisms in childhood immune thrombocytopenia. Clin Dev Immunol (2012) 0.82
T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol (2003) 0.81
Alloimmunization to transfused platelets requires priming of CD4+ T cells in the splenic microenvironment in a murine model. Transfusion (2011) 0.80
Immune thrombocytopenia: getting back to basics. Am J Hematol (2012) 0.79
Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia. J Clin Immunol (2011) 0.78
CTLA4-Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice. Transfusion (2012) 0.78
Effects of CD70 and CD11a in immune thrombocytopenia patients. J Clin Immunol (2011) 0.77
Bmi-1 regulates autoreactive CD4+ T cell survival in immune thrombocytopenia patients. J Clin Immunol (2012) 0.77
RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion (2011) 0.77
Atopic dermatitis and association of risk for primary immune thrombocytopenia and autoimmune diseases among children: A nationwide population-based cohort study. Medicine (Baltimore) (2016) 0.77
Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics (2010) 0.77
The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP. BMC Immunol (2017) 0.75
Advances in Diagnosis and Treatments for Immune Thrombocytopenia. Clin Med Insights Blood Disord (2016) 0.75
Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP). BMC Blood Disord (2004) 0.75
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J Clin Med (2017) 0.75
Platelets: essential components of the immune system. Curr Trends Immunol (2015) 0.75
Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia. Open Med (Wars) (2016) 0.75
The aberrant expression of microRNAs and correlations with T cell subsets in patients with immune thrombocytopenia. Oncotarget (2016) 0.75
A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs? Br J Haematol (2014) 0.75
Combination therapy of rituximab and corticosteroids for patients with refractory chronic immune thrombocytopenic purpura: report of two cases. Contemp Oncol (Pozn) (2013) 0.75
Regulatory T Cells in Patients with Idiopathic Thrombocytopenic Purpura. Turk J Haematol (2016) 0.75
Absence of association of interleukin-18 gene polymorphisms with primary immune thrombocytopenia in a Chinese Han population. DNA Cell Biol (2014) 0.75
Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C. World J Gastroenterol (2006) 0.75
Percentage of Memory B Lymphocytes and Regulatory T Lymphocytes in Peripheral Blood are Low but Not Predictive of Therapy outcomes in Newly Diagnosed Adult Patients with Primary Immune Thrombocytopenia. Indian J Hematol Blood Transfus (2017) 0.75
Are randomized clinical trials the only truth? Not always. J Thromb Haemost (2006) 3.34
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet (1993) 2.12
Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro Surveill (2014) 2.02
Nama keratopathy. Br J Ophthalmol (1973) 1.87
Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur J Immunol (1992) 1.83
Saccharomyces cerevisiae Mob1p is required for cytokinesis and mitotic exit. Mol Cell Biol (2001) 1.81
Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost (2005) 1.70
Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet (2002) 1.56
Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube-H, a sodium citrate solution supplemented with theophylline, adenosine, and dipyridamole. Am J Hematol (1995) 1.45
A survey of red cell use in 45 hospitals in central Ontario, Canada. Transfusion (1996) 1.44
A laparoscopic approach to partial splenectomy for children with hereditary spherocytosis. Surg Endosc (2006) 1.42
Prenatal diagnosis of neonatal alloimmune thrombocytopenia using an allele-specific oligonucleotide probe. Prenat Diagn (1993) 1.40
Speech perception deficits in poor readers: a reply to Denenberg's critique. J Learn Disabil (2004) 1.40
Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood (1991) 1.29
Trabeculectomy in a Black American glaucoma population. Br J Ophthalmol (1976) 1.23
Scleral patch grafts with Molteno setons. Ophthalmic Surg (1987) 1.23
Optimal conditions for the use of sulphydryl compounds in dissociating red cell antibodies. Vox Sang (1976) 1.19
Thrombin-triggered platelet apoptosis. J Thromb Haemost (2006) 1.18
Rapid separation of CD4+ and CD19+ lymphocyte populations from human peripheral blood by a magnetic activated cell sorter (MACS). Cytometry (1993) 1.17
National survey of neonatal transfusion practices: I. Red blood cell therapy. Pediatrics (1993) 1.17
Survey of ocular disease among the Nama people of South West Africa. Br J Ophthalmol (1973) 1.16
Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion (2001) 1.16
Preparation of red cells coated with C4 and C3 subcomponents and production of anti-C4d and anti-C3d. Vox Sang (1976) 1.15
Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. J Pediatr (1997) 1.10
Endophthalmitis after trabeculectomy. Arch Ophthalmol (1978) 1.07
Bilateral macular coloboma, keratoconus, and retinitis pigmentosa. Ann Ophthalmol (1971) 1.07
Incidence of retinoblastoma in the Bantu of South Africa. Br J Ophthalmol (1976) 1.07
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost (2009) 1.07
Fluorescein fundus angiography in self-induced solar retinopathy. A case report. Can J Ophthalmol (1971) 1.06
Comparative study of Watson's and Cairns's trabeculectomies in a Black population with open angle glaucoma. Br J Ophthalmol (1977) 1.06
Rapid clearance of procoagulant platelet-derived microparticles from the circulation of rabbits. J Thromb Haemost (2006) 1.06
Corneal transplantation with associated histopathologic description in xeroderma pigmentosum occurring in a black family. Ann Ophthalmol (1979) 1.05
Delivering labeled teaching images over the Web. Proc AMIA Symp (1998) 1.04
Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol (1999) 1.04
FO gives voicing information even with unambiguous voice onset times. J Acoust Soc Am (1993) 1.01
HLA antigens in acute anterior uveitis in South African blacks. Br J Ophthalmol (1980) 1.00
Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost (2006) 1.00
Coexistence of neuronal messengers--an overview. Prog Brain Res (1986) 0.99
Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs). Med Decis Making (2003) 0.99
Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia (2008) 0.98
Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia (2008) 0.97
Humoral and cellular immune abnormalities in adult hemophiliacs followed over a 2-year period. Diagn Clin Immunol (1987) 0.96
IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol (2001) 0.96
Flow cytometric analysis of platelets from children with the Wiskott-Aldrich syndrome reveals defects in platelet development, activation and structure. Br J Haematol (1997) 0.95
Development of a health-related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes--Kids Life Assessment Tool (CHO-KLAT). Haemophilia (2004) 0.95
Transcatheter coil embolisation: a novel definitive treatment option for intralobar pulmonary sequestration. Heart Lung Circ (2010) 0.95
Clinical trial: 2-L polyethylene glycol-based lavage solutions for colonoscopy preparation - a randomized, single-blind study of two formulations. Aliment Pharmacol Ther (2010) 0.94
Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG). Haemophilia (2008) 0.94
Histopathologic study of the Molteno glaucoma implant in three patients. Am J Ophthalmol (1990) 0.93
Antinociceptive effects and spinal cord tissue concentrations after intrathecal injection of guanfacine or clonidine into rats. Anesth Analg (1987) 0.93
Auditory temporal perception deficits in the reading-impaired: A critical review of the evidence. Psychon Bull Rev (1995) 0.93
Pulmonary disposition of tobramycin. Am Rev Respir Dis (1983) 0.93
Membrane-bound immunoglobulins and complement components on young and old red cells. Transfusion (1985) 0.93
Clinical trial design in haemophilia. Haemophilia (2012) 0.92
Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence. J Thromb Haemost (2004) 0.92
Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfus Sci (1998) 0.92
Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens. Blood (2000) 0.91
Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br J Haematol (1996) 0.91
Bariatric surgery reduces mortality in Swedish men. Br J Surg (2010) 0.90
Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia (2011) 0.90
Relationship of myoma cell size and menopausal status in small uterine leiomyomas. Arch Pathol Lab Med (2000) 0.89
Higher thrombin concentrations are required to induce platelet apoptosis than to induce platelet activation. Br J Haematol (2007) 0.89
Congenital hypopituitarism and conjugated hyperbilirubinemia in two infants. Am J Dis Child (1978) 0.88
Cavitating pneumonia caused by Corynebacterium group JK. J Clin Microbiol (1988) 0.88
Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood (1999) 0.88
Various parameters of diabetic retinopathy among clinic populations. Ann Ophthalmol (1975) 0.87
Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost (2012) 0.87
Thiol-disulfide isomerization in thrombospondin: effects of conformation and protein disulfide isomerase. Blood (1997) 0.87
Dahlak blindness. Br Med J (1972) 0.87
Comparison of low-molecular-weight products following reaction of C3-C3b with C3b inactivator and with trypsin. Vox Sang (1977) 0.86
Quantification of antibodies to the C3d subcomponent of human C3. Immunology (1977) 0.86
Antinociceptive and 'neurotoxic' actions of somatostatin in rat spinal cord after intrathecal administration. Pain (1988) 0.86
The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol (1998) 0.85
Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res (1994) 0.85
National survey of neonatal transfusion practices: II. Blood component therapy. Pediatrics (1993) 0.85
Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura. Am J Hematol (1991) 0.85
Cross-cultural validation of the CHO-KLAT and HAEMO-QoL-A in Canadian French. Haemophilia (2011) 0.85
Further observations on the preparation of antiglobulin reagents reacting with c3d and c4d on red cells. Vox Sang (1977) 0.85
The changing face of hepatitis in boys with haemophilia associated with increased prevalence of obesity. Haemophilia (2011) 0.84
Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant. Transfus Med (1999) 0.84
Assessment of complement binding by anti-D and anti-M antibodies employing labelled antiglobulin antibodies. Br J Haematol (1980) 0.84
Hepatitis A and B immunization for individuals with inherited bleeding disorders. Haemophilia (2009) 0.83
When should prophylaxis therapy in inhibitor patients be considered? Haemophilia (2011) 0.83
Autoimmune hemolytic anemia: a history. Transfus Med Rev (2000) 0.83
Improved survival in severe acquired aplastic anemia of childhood. Bone Marrow Transplant (2000) 0.83
Comparison of platelet immunity in patients with SLE and with ITP. Transfus Sci (2000) 0.83
Intraarticular methylprednisolone therapy in hemophilic arthropathy. Am J Hematol (1988) 0.83